Table 3.

Median (IQR) values of IL-6, IL-8, CTX-II, RANKL and OPG serum levels at baseline and 8 weeks after initiation of TCZ treatment

	Baseline	Week 8	P value
IL-6 (pg/mL)
Total	9.1 (1.1–14.8)	34.2 (25.4–51.9)	0.001
Responders	3.6 (1.2–10.7)	33.7 (20.2–47.8)	0.005
Non-responders	16.9 (13.4–20.8)	34.2 (32.0–48.3)	0.068
IL-8 (pg/mL)
Total	15.3 (11.5–20.1)	15.3 (12.8–21.5)	0.638
Responders	14.6 (10.2–20.1)	15.8 (11.2–21.5)	0.445
Non-responders	19.1 (14.2–23.2)	15.3 (13.6–35.5)	1.000
RANKL (pmol/mL)
Total	0.11 (0.05–0.25)	0.20 (0.15–0.38)	0.013
Responders	0.09 (0.05–0.27)	0.21 (0.18–0.38)	0.008
Non-responders	0.18 (0.05–0.28)	0.15 (0.08–0.69)	0.465
OPG (pmol/L)
Total	7.04 (5.04–9.79)	7.20 (5.28–8.65)	0.272
Responders	7.33 (5.04–10.25)	7.20 (5.28–8.65)	0.285
Non-responders	6.62 (4.79–9.14)	6.39 (4.57–8.89)	1.000
CTX-II (ng/mL)
Total	1525.1(1178.4–1672.6)	1715.1 (1393.1–2660.1)	0.433
Responders	1518.0(1172.3–1647.9)	1782.54(1310.6–2668.3)	0.169
Non-responders	1598.8(1369.9–3242.6)	1579.18(1420.0–2600.2)	0.465

CTXII, C-terminal crosslinked telopeptide type II collagen; IL-6, interleukin-6; IL-8, interleukin-8; OPG, osteoprotegerin; RANKL, receptor activator for nuclear factor-κB ligand.